Are you Dr. Matsuda?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 11 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
2665 30th St
Suite 204
Santa Monica, CA 90405Phone+1 310-396-4558Fax+1 310-396-4598
Summary
- Dr. Kazuko Matsuda, MD is a psychiatrist in Santa Monica, California. She is currently licensed to practice medicine in California.
Education & Training
SUNY Downstate Health Sciences UniversityResidency, Psychiatry, 1990 - 1994
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Psychiatry, 1989 - 1990
Certifications & Licensure
CA State Medical License 2005 - 2026
Clinical Trials
- Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS Start of enrollment: 2021 Jan 11
Publications & Presentations
PubMed
- 173 citationsPhase 2 trial of ibudilast in progressive multiple sclerosisRobert J. Fox, Christopher S. Coffey, Robin Conwit, Merit Cudkowicz, Trevis Gleason
The New England Journal of Medicine. 2018-08-30 - 22 citationsMN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design.Bjorn Oskarsson, Nicholas J. Maragakis, Richard Bedlack, Namita Goyal, Jenny A Meyer
Neurodegenerative Disease Management. 2021-11-24
Press Mentions
MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-166 (Ibudilast) in ALS Presented at the 30th International Symposium on ALS/MND in Perth, AustraliaDecember 4th, 2019
Canada Approves New Patent Covering Ibudilast’s Use for ALS TreatmentNovember 5th, 2019
MediciNova Appoints Kazuko Matsuda to Its Board of DirectorsSeptember 11th, 2019
